←
Dr. E. L. Stone4,951 posts
Dr. E. L. Stone avatar

Dr. E. L. Stone

@StoneEL2

#PhD #Tcells #Immunotherapy #TumorImmunity #Immunology Tweets are my opinion, retweets not endorsement. Recovering academic. she/her. Now design Next-Gen CPIs.

◷ Joined June 2018▧ 56 Photos and videos
Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·14 Jul 2021

(4) Nextgen IL2s w reduced binding to CD25, induce less Treg proliferation and have had encouraging results in trials. Our third-gen anti-CTLA-4 with limited ability to block CTLA-4 induces less Treg proliferation, has enhanced anti-tumor efficacy but reduced toxicity in models

Dr. E. L. Stone avatar
⟳ Dr. E. L. Stone retweeted
Dr. E. L. Stone@StoneEL2·Apr 22

I was delighted to help reveal the first clinical data for GIGA-564, a differentiated, non-blocking anti-CTLA-4 mAb designed to selectively deplete intratumoral Tregs.

Post attachment
Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·Apr 22

In this on-going first-in-human study GIGA-564 demonstrated a favorable safety profile while exhibiting early signals of anti-tumor activity in solid tumors (including 2 RECIST1.1 responses). A big thanks to everyone who shared their thoughts on the data and program.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·Apr 22

#AACR2026 showcased how quickly oncology research is moving. It is inspiring to be surrounded by so many researchers working to better understand and hopefully treat cancer.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·Apr 18

Excited to be at @AACR to help share the first clinical data for GIGA-564, a differentiated, non-blocking anti-CTLA-4 mAb designed to deplete intratumoral Tregs, including a favorable safety profile and monotherapy RECISTv1.1 responses. #AACR2026 grifols.com/en/view-news/-/n…

Sergio Quezada avatar
⟳ Dr. E. L. Stone retweeted
Sergio Quezada@squezadd·21 May 2024

Absolutely honoured to be elected Fellow of the Academy of Medical Sciences together with amazing ⁦@ucl⁩ colleagues!! Thanks to ⁦⁦@uclcancer⁩ ⁦@CR_UK⁩ and my amazing team ⁦@QuezadaLab⁩ ucl.ac.uk/news/2024/may/ucl-…

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·21 May 2024

Late last year, we announced IND Safe-to-Proceed for this molecule, and now, through cross-functional collaboration with teams across Grifols, GigaGen, and the NCI, this molecule is being tested in a Phase 1 study.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·21 May 2024

GIGA-564 is differentiated anti-CTLA-4, instead of blocking CTLA-4 binding to its ligands, it is designed to work through an Fc receptor mechanism of action.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·21 May 2024

After joining GigaGen we selected a monoclonal antibody that was identified because of GigaGen's proprietary microfluidics-based antibody discovery platform and began to develop this antibody that would become known as GIGA-564.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·21 May 2024

In 2018 I decided my true passion in science was to attempt to apply it to benefit patients with unmet need. From that point on the story becomes about following the science and passion and the potential of truly cross functional teams.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·21 May 2024

In 2015, I decided to focus my new academic lab on understanding the multiple mechanisms of action of 1st generation anti-CTLA-4s. Our lab and others went on to show that a major mechanism of action of anti-CTLA-4s is through an Fc dependent function of these antibodies.

Dr. E. L. Stone avatar
Dr. E. L. Stone@StoneEL2·21 May 2024

This achievement has provided me with an opportunity to reflect on how we got here, and the story starts with following the science. In 2009, I became interested in how FOXO1 regulates Ctla4, and how this regulation was a crucial component of FOXO1 function.